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Abstract
Irritable bowel syndrome (IBS) is the most frequently 
diagnosed functional gastrointestinal disorder in prima-
ry and secondary care. It is characterised by abdominal 
discomfort, pain and changes in bowel habits that can 
have a serious impact on the patient’s quality of life. 
The pathophysiology of IBS is not yet completely clear. 
Genetic, immune, environmental, inflammatory, neuro-
logical and psychological factors, in addition to visceral 
hypersensitivity, can all play an important role, one that 
most likely involves the complex interactions between 
the gut and the brain (gut-brain axis). The diagnosis 
of IBS can only be made on the basis of the symptoms 
of the Rome Ⅲ criteria. Because the probability of 
organic disease in patients fulfilling the IBS criteria is 
very low, a careful medical history is critical and should 
pay particular attention to the possible comorbidities. 
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Nevertheless, the severity of the patient’s symptoms or 
concerns sometimes compels the physician to perform 
useless and/or expensive diagnostic tests, transform-
ing IBS into a diagnosis of exclusion. The presence of 
alarming symptoms (fever, weight loss, rectal bleeding, 
significant changes in blood chemistry), the presence 
of palpable abdominal masses, any recent onset of 
symptoms in patient aged over 50 years, the presence 
of symptoms at night, and a familial history of celiac 
disease, colorectal cancer and/or inflammatory bowel 
diseases all warrant investigation. Treatment strategies 
are based on the nature and severity of the symptoms, 
the degree of functional impairment of the bowel hab-
its, and the presence of psychosocial disorders. This 
review examines and discusses the pathophysiological 
aspects and the diagnostic and therapeutic approaches 
available for patients with symptoms possibly related to 
IBS, pointing out controversial issues and the strengths 
and weaknesses of the current knowledge.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The pathophysiology of irritable bowel syn-
drome (IBS) is not definitely known and many funda-
mental questions remain unanswered about its patho-
physiology, diagnosis and therapy. Conflicting results 
reflect the largely overlapping data of healthy controls 
and the wide heterogeneity of the IBS patients. This 
review summarises the main pathophysiological as-
pects, practical diagnostic approaches and therapeutic 
management strategies for patients with symptoms 
possibly related to IBS, in addition to pointing out some 
controversial issues and pointing out the strengths and 
the weaknesses of our current knowledge.
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INTRODUCTION
Irritable bowel syndrome (IBS) is quite prevalent in the 
general population (from 5% to 20%) and represents the 
functional gastrointestinal (GI) disorder most frequently 
encountered in primary and secondary care[1,2]. IBS is 
characterised by abdominal discomfort, pain and changes 
in bowel habits (constipation and/or diarrhoea)[3] that 
wax and wane over time. Moreover, it is often associated 
with other functional digestive and non-digestive disor-
ders[4-8].
The pathophysiology of  IBS is not definitely known 
but most likely involves central and peripheral mecha-
nisms. A disruption of  the so called “brain-gut axis” that 
determines changes in digestive motility and secretion, 
causes visceral hypersensitivity and leads to cellular and 
molecular abnormalities in the enteroendocrine and im-
mune systems has been suggested. In addition, genetic 
factors, infections and alterations of  the intestinal micro-
biota, inflammation and food intolerance and/or hyper-
sensitivity could play a role by altering the integrity of  the 
intestinal barrier and increasing intestinal permeability[9,10]. 
Up to now, unfortunately, conflicting results have been 
achieved, most likely reflecting the largely overlapping 
data of  healthy controls and the wide heterogeneity of  
the IBS population.
The direct and indirect costs of  the syndrome are 
significant, as IBS can have a serious impact on patient 
quality of  life. Because there are not yet any available 
biological markers or resolving therapies, the patient may 
undergo expensive tests and treatments[11-13].
The therapeutic approach depends on the intensity of  
symptoms and the degree of  psychosocial comorbidities. 
Initial treatment is directed towards education, reassur-
ance and lifestyle modification. In a second phase, an 
appropriate pharmacotherapy can be proposed on the 
basis of  individual or global intestinal symptoms and/or 
psychological disturbances.
Many different drugs have been suggested for IBS 
treatment, but their real benefits are very debatable. 
Based on the multifaceted pathophysiology of  the dis-
ease, it is unlikely that drugs acting on a single receptor 
and/or a unique pathophysiologic mechanism would be 
able to provide any substantial therapeutic gain over a 
placebo in this disease, for which the placebo response 
rate is approximately 40%[14].
Essentially, we are still far from having discovered 
the magic bullet capable of  treating all IBS symptoms. 
Although many papers have been published on this 
syndrome in recent years, up to now, many fundamental 
questions remain unanswered about its pathophysiology, 
diagnosis and therapy.
This review summarises the main pathophysiological 
aspects, practical diagnostic approaches and therapeutic 
management strategies for patients with symptoms pos-
sibly related to IBS, in addition to pointing out some 
controversial issues and pointing out the strengths and 
the weaknesses of  our current knowledge.
A search of  the literature was carried out using the 
online databases of  PubMed, Medline and Cochrane to 
identify articles published in English concerning patho-
physiology, diagnosis and treatment of  IBS.
PATHOPHYSIOLOGICAL ASPECTS
The pathophysiology of  IBS, as in all functional digestive 
disorders, is complicated because there is no clearly iden-
tified pathophysiological basis for the disease. In fact, IBS 
is identified by a combination of  chronic or recurrent 
GI symptoms in the absence of  structural abnormalities 
(radiological/endoscopic) or biomarkers capable of  posi-
tively identifying this condition. Aside from these draw-
backs, the clinical manifestations of  IBS are themselves 
extremely heterogeneous, a sort of  “semantic umbrella” 
under which different clinical situations related to pheno-
typic aspect (traditionally subtyped as diarrhoea predomi-
nant, constipation predominant and mixed type) and the 
modality of  clinical onset (post-infectious, food-related, 
stress-linked, etc.) fall[15].
The aetiology of  IBS is multifactorial. Many pathoge-
netic factors, in various combinations and not all neces-
sarily present in each patient, can play an important role 
(Table 1). Genetics, immune factors, environmental influ-
ences, inflammatory and infective agents, neurological 
and psychological factors, hypersensitivity to food and to 
bile salts and altered intestinal microbiota and permeabili-
ty can all influence the brain-gut axis, leading to abnormal 
GI function and motility. It is unclear which among these 
factors is the trigger or how these conditions converge 
to initiate the IBS; previous studies aiming to identify a 
factor as more of  a trigger over the others all failed to 
distinguish any one trigger.
The genetic factors have been extensively studied. 
Up to 33% of  IBS patients have a family history of  
IBS, compared to 2% of  controls[16]. There is a higher 
prevalence of  the disease in families of  patients with 
IBS compared to the families of  the spouses without 
IBS[17]. Moreover, some studies have reported a higher 
prevalence in monozygotic twins compared with hetero-
zygotes, indicating a hypothetical genetic component[18]. 
However, other studies[19] demonstrated that having a 
parent with IBS was a better predictive factor than having 
a twin affected with IBS, suggesting that the environmen-
tal factor is more important.
The genetic factors involved in the pathogenesis 
of  IBS has also been evaluated by a number of  studies 
investigating the possible role of  gene polymorphisms 
coding for serotonin (SERT), cholecystokinin (CCK) 
receptors 1, anti-inflammatory and pro-inflammatory in-
terleukins and alpha 2 adrenergic receptors[20-22]. As sero-
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tonin was involved in the regulation of  digestive motility, 
secretion and visceral sensitivity, particular investigative 
emphasis has been placed on polymorphisms of  the gene 
regulating the reuptake of  serotonin (SERT), which can 
induce a variation of  its synaptic concentration[23]. SERT 
polymorphisms are not related to the development or 
onset of  IBS, but rather to a different clinical expression, 
a greater perception of  abdominal pain and an increased 
dissatisfaction regarding bowel habits[24].
Recently, a “biopsychosocial” model[25,26] has been 
introduced, in an attempt to integrate and harmonise the 
different factors (genetic, environmental and psychologi-
cal) acting in a synergistic way to produce these symptoms. 
These deficiencies in understanding the pathophysi-
ological mechanisms of  IBS have a heavy negative effect 
on clinical practice and may explain the disappointing re-
sults of  previous therapeutic attempts, as well as the high 
costs of  management. Currently, there is no single drug 
that is able to treat all of  the symptoms related to IBS; 
rather, a “drug cocktail” is administered, having different 
effects on different symptoms.
Previous studies[27] have considered this syndrome a 
result of  alterations in the normal digestive motility pat-
tern, the so-called “spastic colon”. Subsequently, much 
interest was directed toward visceral hypersensitivity, un-
der the hypothesis that IBS patients experienced visceral 
stimuli more strongly than healthy subjects. Later, IBS 
came to be considered a two-way interaction between the 
gut and the brain, with much interest directed not only 
toward the activation/deactivation of  afferent and effer-
ent nervous stimuli but also toward the effects of  neuro-
modulators.
The possibility that IBS could be initiated after an 
enteric infection and the evidence that, in inflammatory 
bowel disease limited to the mucosa, patients suffer from 
enhanced sensory perception and motor dysfunction 
have driven researchers to study these as further potential 
causes of  IBS.
Some previous studies[28,29] attempted to assess wheth-
er an abnormal motility pattern is typical in cases of  IBS; 
however, despite identifying cluster contractions in phase 
Ⅱ of  the migrating motor complex in the jejunum, prop-
agated ileal contractions related to pain and an increased 
postprandial motor activity of  the colon, up to now, all at-
tempts made have failed to reach a single typical pattern.
An altered colonic transit rate [accelerated in IBS 
and diarrhoea (IBS-D) and slowed in IBS with consti-
pation (IBS-C)] was described in some studies[30,31] but 
these results have not been confirmed by more recent 
studies[32,33]. Salvioli et al[34] reported a decreased capacity 
of  the motor activity in the small intestine to eliminate 
intestinal gas, resulting in abdominal distension and typi-
cal symptoms of  IBS. IBS patients likely experience psy-
chological stress, foods, neurotransmitters and/or rectal 
or bowel distension, which can lead to an altered motor 
response that leads to the same motor events being per-
ceived more strongly and painfully[35].
Visceral hypersensitivity in IBS patients is supported 
by several studies[36-38]. Verne et al[39] used functional nu-
clear magnetic resonance (RMN) to show that a mechani-
cal stimulus (rectal distension) active different regions of  
the brain in healthy volunteers, compared to patients with 
IBS. Unfortunately, this technique is expensive and not 
widely available. Moreover, comorbidities, such as fibro-
myalgia and psychological disturbances, can significantly 
affect its outcome.
Psychological disorders, including sexual and physical 
abuse, result in a high percentage of  patients with func-
tional disorders. Even if  the disorders are not directly re-
sponsible for the onset or progression of  the IBS symp-
toms, they certainly determine a different perception of  
the symptoms and result in more frequent requests for 
medical aid. In fact, these disorders are more common in 
IBS patients who seek medical care than in patients who 
do not ask for medical help or healthy volunteers[15,40].
Psychological distress and disorders can affect the 
brain-gut axis, promoting the release of  corticotropin-
releasing hormone, which is able to influence mood, 
digestive motility, permeability, visceral sensitivity and in-
flammatory pathways via neuroendocrine and autonomic 
outflows[41-44]. Dinan et al[44] showed that physical and 
mental stress in IBS patients increased the levels of  pro-
inflammatory interleukins, activating both the hypotha-
lamic-autonomic nervous system and the hypothalamic-
pituitary-adrenal (HPA) axes and consequently increasing 
the serological adreno-cortico-tropic-hormone and cor-
tisol levels. Recent studies[44,45] introduced the hypothesis 
that IBS could be an inflammatory disorder that is sup-
ported by a dysregulation of  the HPA.
On the other hand, it has been shown that physical 
and psychological stress activates different regions of  the 
brain among patients with IBS than among healthy vol-
unteers. In particular, IBS patients have a greater activa-
tion of  the mid-anterior cingulate cortex, an area linked 
to anxiety, fear and hypervigilance[46]. This area is the 
target of  many antidepressant drugs and psychotherapy. 
In healthy controls, stress instead activates the perigenual 
area, from which originate the descending inhibitory 
pathways that control visceral afferents to the posterior 
horn of  the spinal cord[47].
A continuous and mutual interaction between the gut 
and the brain is made possible through the autonomic 
nervous system and the enteric nervous system via neu-
roendocrine mediators (VIP, 5HT, Ach, NO, NO, CCK, 
etc.); this system comprises the so-called “gut - brain axis”. 
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Table 1  Factors potentially involved in the pathogenesis of 
irritable bowel syndrome
Altered intestinal motility
Food intolerance/allergy
Enteric infection/inflammation
Altered intestinal immunity
Altered gut microbiota
Genetics
Psychological distress and disorders; sexual abuse
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In post-infectious IBS and D-IBS, intestinal perme-
ability has also been studied. The findings included a 
decreased expression and remodelling of  the structural 
proteins constituting the epithelial “tight junctions” in 
the cells of  the small intestine and colon. These changes 
increased the intestinal permeability, resulting in an easier 
passage of  antigenic material through the epithelium and 
a stimulation of  the intestinal immune system (especially 
mast cells) with the production of  the proteases, hista-
mine and prostanoids able to maintain the permeability 
and to produce abnormal neuronal responses, inducing 
the motor and sensory results typical in IBS[42].
Based on these results, it is evident that preserv-
ing, maintaining or restoring the normal composition 
of  the intestinal microbiota is essential for good bowel 
function[42]. The intestinal microbiota is a major target 
of  many therapeutic options for relieving IBS symp-
toms. The colon of  each individual contains from 300 
to 500 different species of  bacteria. Thus, each of  our 
microbiota is individual and unique. The microbiota is 
influenced by the environment, diet, previous infections, 
genetics, age, and antibiotic therapy. In normal condi-
tions, the lactobacilli and bifidobacteria bind to epithelial 
cells, inhibiting the binding of  pathogens and reinforcing 
the defences of  the mucosal barrier. In addition, lactoba-
cilli and bifidobacteria do not produce gas by fermenting 
carbohydrates and inhibiting the growth of  the Clostridia 
species, which do produce this effect. Lactobacilli and bi-
fidobacteria were found to be decreased in IBS patients, 
and their activities were found to be heavily compro-
mised[56]. Moreover, some evidence indicates that probi-
otics affect intestinal fermentation and stabilise the in-
testinal microbiota, normalising the relationship between 
pro-inflammatory and anti-inflammatory cytokines with 
beneficial effects on intestinal inflammation, permeability 
and visceral sensitivity[57,58].
Unfortunately, at present, there are intrinsic difficul-
ties in clearly establishing the role of  the gut microbiota 
in the pathophysiology of  IBS, both due to the great het-
erogeneity in the clinical presentation of  IBS and to the 
limitations of  the available studies (study design, length 
of  observation, small sample, etc.).
Finally, the role of  food in IBS merits specific men-
tion. Patients with IBS tend to declare that their symp-
toms are often exacerbated by meals or by certain foods 
(sweeteners, fats, etc.). The classical IgE-mediated food 
allergy does not seem to play an important role in IBS. 
In the recent past, high levels of  the specific IgG4 for 
wheat, beef, pork and lamb were found in IBS patients, 
compared to healthy subjects, and based on this, an ex-
clusion diet was proposed[59]. On the other hand, this 
subgroup of  Ig seems to be only an epiphenomenon of  
mucosal production, according to recent evidence[60].
In any case, up to 60% of  patients with IBS reported 
a worsening of  symptoms after food intake, in particular 
after specific foods like milk and dairy products, wheat, 
onions, beans, spices, cabbage, red meat, fried, smoked 
products, and caffeine. These foods represent the so-
Signals received from the GI tract affect the brain that, in 
turn, can affect the motility, secretion and immune func-
tions of  the digestive tract. Thus, alterations to this sys-
tem may cause many digestive disorders, and particularly 
IBS, compared to normal, unaltered subjects[41,48,49].
The neuroendocrine system is potentially involved 
in the pathogenesis of  IBS. This system is very complex 
and consists essentially of  two components.
The endocrine cells (at least 14 endocrine or paracrine 
cell populations), which are distributed between the epi-
thelial cells of  the digestive mucosa and directly in con-
tact with the intestinal lumen and its contents; and the 
nerve fibres (peptidergic, serotonergic, nitrergic, etc.) of  
the enteric nervous system[15].
Motility, secretion, absorption and intestinal microcir-
culation are all influenced by this system by the means of  
several mediators that have endocrine (released directly 
into the blood stream), autocrine/paracrine (local ef-
fects) or neuroendocrine (released from synapses into the 
bloodstream) functions[41].
An alteration to this system has been hypothesised, 
in which a decreased density of  cells producing gastric 
inhibitory polypeptide (GIP) and somatostatin (in D-IBS 
and C-IBS) and in those producing secretin and CCK 
(in D-IBS) was reported in the small intestine, whereas 
a lower expression of  cells producing 5-hydroxytrypta-
mine and PYY was detected in the colons of  patients 
with D-IBS and C-IBS[15,41]. An abnormal inflammatory 
response to different events (stress, infections, food, etc.) 
could be responsible for the abnormal cellularity in the 
colonic mucosa and the increased concentration of  pro-
inflammatory interleukins detected in the colons of  some 
IBS patients[50]. These studies suggest that the activation 
of  mast cells, macrophages or leukocytes producing in-
flammatory mediators is able to affect the motility, secre-
tion, sensitive nerve endings and ultimate perception of  
pain.
Biopsies from the colons of  IBS patients showed an 
increased activation of  lymphocytes and mast cells in 
close proximity to the enteric neurons, with increased 
production of  cytokines and other proinflammatory and 
vasoactive peptides[51,52]. Degranulation of  these cells 
(especially mast cells) has been associated with the onset 
of  the typical abdominal pain endured by IBS patients[53]. 
Moreover, the density of  immunocompetent cells gradu-
ally increases on a spectrum from controls to patients 
with IBS, then to patients with microscopic colitis and, 
finally, to those with ulcerative colitis[54].
Inflammation can also result from a previous enteric 
infection. The onset of  IBS follows an infection in ap-
proximately 10% of  patients. In these patients, there are 
increases in the levels of  CD3 serum lymphocytes, CD8 
intraepithelial lymphocytes, and macrophage calprotectin-
positive cells. Moreover, cells producing serotonin and 
CCK were found to be increased in the small bowel, 
while those producing serotonin and PYY were decreased 
in the colon. These alterations were usually transient but 
tended to persist in patients who developed IBS[55].
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called fermentable oligosaccharides, disaccharides, mono-
saccharides and polyols (FODMAPs). However, studies 
supporting this are limited and demonstrate only a partial 
improvement in patients after the restriction of  these 
foods. More frequently, IBS patients seem to have an ex-
aggerated gastric-colic reflex after eating any item of  food.
In recent years, it has been observed that the inges-
tion of  gluten causes abdominal discomfort and IBS-
like symptoms in subjects without a diagnosis of  celiac 
disease (the so-called gluten sensitivity).
At the moment, the mechanisms responsible for these 
symptoms are not clear. Most likely, the gluten, as other 
well-known factors, alters the intestinal permeability, 
activating the enteric and autonomous nervous systems 
and producing the typical symptoms of  IBS. Recently, 
authors have disagreed on the topic of  gluten sensitivity, 
instead attempting to explain the problem with a simpler 
hypothesis: gluten-rich foods may cause symptoms with 
the same mechanisms of  the FODMAPs[61,62]. The posi-
tive effect of  the gluten-free diet on abdominal disorders 
could be due to the drastic reduction of  FODMAPs that 
is inevitable in a diet of  this type.
Up to now, the available results in the literature con-
flict; thus, further studies are needed to clarify this in-
triguing matter.
DIAGNOSTIC APPROACHES
A careful medical history is critical for the evaluation of  
a patient with a possible diagnosis of  IBS. Particular at-
tention has to be devoted to many different issues, such 
as dietary habits, therapies (especially the intake of  drugs 
capable of  altering the bowel frequency and/or causing 
abdominal pain), the degree of  physical activity, comor-
bidities, previous surgical interventions, presence of  
symptoms suggesting anxiety or depression, and recent 
trips to exotic locations[3,63].
In the absence of  accepted and shared biological 
markers, symptoms remain the cornerstone for the diag-
nosis of  IBS.
Regarding the symptom “pain”, it is useful to assess 
its type (cramping, tensive, stabbing, burning), localisa-
tion, frequency, duration, mode of  occurrence and pos-
sible changes in relation to defecation, to food intake (or 
to intake of  particular foods), to stressful events and to 
the menstrual cycle[63,64].
As for abdominal distension or tension, it is manda-
tory to ask the patient if  it is visible from others or if  it 
is otherwise measurable (changes in size, inability to tie 
the skirt or pants, etc.). Additionally, patients should be 
asked whether their pain gets worse at certain times or 
improves with evacuation or emission of  the flatus.
It is also necessary to investigate the characteristics 
of  the defecation: difficult or prolonged, painful or sim-
ply incomplete, the presence of  a sensation of  anorectal 
blocking, the need for manual help, the presence of  inef-
fective attempts or, on the contrary, of  an urgency at def-
ecation and real episodes of  faecal incontinence[64].
Moreover, it is important to check for the presence of  
blood, mucus or pus in the faeces and to assess the usual 
shape of  the stool using the Bristol Scale that, by relating 
the rate of  intestinal transit with faecal consistency, pro-
vides a visual aid to help the patient better classify a topic 
otherwise difficult to objectify[65].
Additionally, it is mandatory to look for the pos-
sible co-morbidities that can occur in a patient with IBS, 
because they can increase the perception of  the disease 
severity[8,13,66,67].
In Table 2, the most frequent co-morbidities are repre-
sented. These share common characteristics, such as the 
following: (1) a higher prevalence in females; (2) patho-
physiology linked to low-grade inflammation, stress, 
somatisation, hypersensitivity, changes in the central 
processing of  peripheral afferents and/or alterations of  
substances acting as neuromodulators; (3) a diagnosis 
mainly based on symptoms; (4) possible responsiveness 
to antidepressant medications and cognitive-behavioural 
therapies; (5) frequent multidisciplinary management; 
and (6) a considerable reduction of  the quality of  life and 
high, direct and indirect, costs.
The presence of  alarm symptoms, the so-called “red 
flags” like fever, weight loss, rectal bleeding, and signifi-
cant changes in blood chemistry, should be investigated, 
as well as the presence of  palpable abdominal masses, 
any recent onset of  symptoms in patients aged over 50 
years, the presence of  symptoms at night, and a familiar 
history positive for celiac disease, colorectal cancer and/
or inflammatory bowel disease[64,68].
Still, some authors[69] believe that the accuracy of  the 
“alarm symptoms” is disappointing. In particular, rectal 
bleeding and nocturnal pain would be of  little value in 
discriminating patients with IBS from patients with or-
ganic disease, while anaemia and weight loss would have 
low sensitivity, but high specificity, to identify an organic 
disease.
A physical examination would not be very rich in in-
formation, as it could only detect abdominal tenderness 
(localised or diffuse) and abdominal hypertympanism or 
bowel sounds at auscultation, but this practice reassures 
the patient and can provide a first, coarse exclusion of  
organic diseases (abdominal masses, etc.). The examina-
tion should include the inspection of  the anorectal region 
and a digital rectal examination, preferably in the left-
lateral decubitus, which would provide useful information 
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Table 2  Most frequently reported comorbidities in irritable 
bowel syndrome patients
Functional dyspepsia and functional heartburn
Fibromyalgia
Chronic fatigue syndrome
Back pain
Multiple chemical sensitivity syndrome
Post-traumatic stress disorder
Psychological/psychiatric disorders
Sleep disturbances
Migraine and tension headaches
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about the dynamics of  the pelvic floor, especially if  any 
functional alteration is suspected. Thus, the presence of  
comorbidities and organic diseases can be detected[63,70-72].
The use of  specifically dedicated scores to measure 
the impairment of  the quality of  life and symptom sever-
ity has been debated in clinical practice, both at the initial 
stages and later, in order to verify the effectiveness of  the 
therapy administered[73]. Indeed, any such scoring systems 
are not widely used outside of  clinical trials, even if  they 
do not seem time-consuming or difficult to use[74-77].
Can a diagnosis of  IBS be made only using only 
symptom-based criteria? The evidence from the literature 
seems reassuring in this respect, because the probability 
of  organic disease arising in patients fulfilling the IBS cri-
teria is very low[78]. Nevertheless, the nature and severity 
of  the symptoms themselves, or of  the patient’s concerns 
and fears, sometimes compel the physician to perform 
unnecessary, useless, and/or expensive diagnostic tests, 
transforming IBS into a diagnosis of  exclusion.
Indeed, in the differential diagnosis, the conditions re-
ported in Table 3 will have to be considered with greater 
or lesser probability[68].
Unfortunately, there are no available biological mark-
ers that clearly identify IBS patients.
Some recent studies have examined faecal lactoferrin 
and calprotectin, which seem quite suitable to differenti-
ate between infectious bursal disease and IBS but are not 
able to provide a certain diagnosis of  IBS[79,80].
Recent studies have investigated some biomarkers 
involved in the pathophysiology of  IBS[45,81]. A recent sys-
tematic review and meta-analysis examined the placebo 
response rate in treatment trials for IBS and demonstrat-
ed a high placebo response[82].
In the case of  a patient with IBS-like chronic recur-
ring abdominal symptoms, the presence of  alarming 
symptoms should first be assessed[68,69,83,84]. In the pres-
ence of  alarming symptoms, further investigation should 
be undertaken. On the contrary, in the case of  Rome Ⅲ 
criteria positivity and in the absence of  alarm symptoms, 
possible comorbidities (which are part of  the IBS man-
agement) should be considered. Serological screening 
for celiac disease and a few basal blood tests have to be 
performed; if  a negative result is returned, it is usually 
sufficient to reassure the patient and to offer advice on 
drug therapies, lifestyle habits and diet. A check-up after 
8-12 wk should be offered, and in cases with sustained 
improvement, the patient will enter into a follow-up pro-
gram (Figure 1).
In the case of  a patient with symptoms in any way 
compatible with irritable bowel syndrome but that did 
not satisfy the Rome criteria, or in the case of  a patient 
with a poor response to the therapy, depending on the 
prevailing symptoms (constipation, diarrhoea, abdominal 
pain/bloating), different options should be considered 
(Figure 1).
In the case of  constipation, dietary habits and behav-
iours, as well as the use of  laxatives, should be checked. 
In the case of  the ineffectiveness of  these measures, if  
not already performed, an assessment of  the thyroid 
function, routine blood tests and screening for celiac 
disease are recommended. In the case of  diarrhoea and 
abdominal pain/distention, lactose breath test (LBT) 
(or simply lactose withdrawal), a faecal blood test, faecal 
Calprotectin or Lactoferrin, stool culture, test for ova 
and parasites, a chemico-physical examination to test for 
Clostridium difficile toxins and an abdominal ultrasound 
aimed at studying the enteric loops should be considered.
If  signs of  a specific disease emerge from the inves-
tigation or from specific treatments, further investigation 
should be initiated. In the case of  a negative outcome, 
it will become mandatory to proceed to the next steps, 
as follows (Figure 1): (1) in the case of  constipation, the 
possibility arises of  performing a colonoscopy, anorectal 
manometry, defecography, intestinal transit time and, in 
carefully selected cases, colonic and gastrojejunal manom-
etry; (2) in the case of  diarrhoea and abdominal pain, it 
will become appropriate to check and eventually change 
the patients’ drugs; (3) in the case of  a failed colonosco-
py, biopsies may be useful; and (4) in the case of  a nega-
tive outcome of  a colonoscopy, the further investigations 
reported in Figure 1 should be considered.
Still, it is mandatory to emphasise that none of  these 
investigations, even those that are costly and unusual, 
should be performed to achieve the diagnosis of  IBS, 
which is essentially based on the Rome Ⅲ criteria, as 
reported above. On the contrary, these tools are to be 
taken into account only in a patient with abdominal 
symptoms that are IBS-like but Rome Ⅲ criteria-negative 
or -equivocal. They may also be used in IBS patients with 
very severe symptoms that require a careful reassessment 
of  the clinical situation.
In IBS, the follow up should be tailored to the pa-
tient, because the disease is characterised by variable 
remissions and relapses, with symptoms waxing and wan-
ing over time, often oddly and sometimes in coincidence 
with stressful events, anxiety, the intake of  certain foods, 
etc. IBS patients usually tend to avoid fixed controls, al-
though, at least at the beginning, a clinical visit 2-3 mo 
after the diagnosis is advised to assess the patient’s adher-
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Table 3  Diseases and conditions considered in the differential 
diagnosis
Celiac disease and malabsorption
Lactose intolerance, fructose intolerance
Inflammatory bowel disease
Lymphocytic and collagenous colitis
Whipple's disease
Colonic cancer
Enteric infections
Metabolism disorders (e.g., thyroid, diabetes, etc.)
Food allergy and intolerance
Endometriosis
SIBO
Neuroendocrine tumors
Drugs
Bellini M et al . IBS pathogenesis, diagnosis and therapy
SIBO: Small intestinal bacterial overgrowth.
ence to therapy and the dietary and behavioural recom-
mendations.
The aim will be to help IBS patients perceive their 
symptoms as part of  a chronic, intermittent disorder, 
learning to live with them. Thus, these patients can re-
join that “silent majority” of  IBS patients who perceive 
her/his symptoms as no more than a nuisance and do 
not seek further special care, doctor visits, or additional 
diagnostic tests.
THERAPEUTIC PERSPECTIVES
Treatment strategies for IBS are based on the nature and 
severity of  the symptoms, the degree of  functional im-
pairment of  the bowel habits, and the presence of  psy-
chosocial comorbidity. In general, milder symptoms relate 
primarily to visceral hypersensitivity and are commonly 
treated symptomatically, with pharmacological agents 
directed at the gut. However, more severe symptoms are 
associated with greater levels of  psychosocial problems 
and often require psychological and antidepressant medi-
cations.
There is limited evidence for the efficacy, safety and 
tolerability of  the therapies currently available for the 
treatment of  IBS. Overall, there is a limited availability of  
pharmacological agents licensed specifically for the treat-
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Chronic/recurrent 
abdominal symptoms
Rome criteria negative Rome criteria positive
Constipation
Clinical evaluation     After 8-12 wk
Follow up Colonoscopy
Anorectal manometry 
Defecography
Colonic transit time 
(Colonic manometry)
(Gastrointestinal manometry)
Further 
investigation 
and/or specific 
therapy
Small bowel radiologic study
EGD endoscopy + biopsies
Screening for food intolerance
GI hormones assay
Entero CT/MRI
Videocapsule
Sorbitol/fructose/glucose 
breath tests
Plain abdominal X-rays
Abdominal CT/MRI
Assessment of  ALA, PBG, porphyrins 
and its metabolites
Small bowel transit 
(radiologic/scintigraphic)
Gastrointestinal manometry
Sorbitol/fructose/glucose breath tests
Further 
investigation 
and/or 
specific 
therapy
RED FLAGS + RED FLAGS -
Exstensive
investigation
Diarrhoea       Abdominal pain/bloating
Consider comorbidities and FBC, ESR, 
CRP and coeliac serology  in IBS-D 
and IBS-M
Routine blood tests, TSH
Coeliac serology
Lactose breath test/lactose withdrawn
Faecal biomarkers (FBT, Calprotectin, Lactoferrin)
Stool culture, test for ova and parasites and 
chemico-physical examination, Cl.difficile toxin
Abdominal ultrasound (also for enteric loops)
Reassurance, 
Dietary suggestions,
Pharmacological treatment
Improvement Follow up
ImprovementNo improvement
Routine blood tests plus TSH 
coeliac serology
Negative
NegativePositive 
Positive Negative
Check/change 
therapy
No improvement
Diarrhoea Negative
Colonoscopy 
+ biopsies
Positive 
Abdominal 
pain/bloating
Check dietary suggestions and laxatives
Figure 1  Diagnostic-therapeutic algorithm in a patient with abdominal symptoms possibly related to irritable bowel syndrome. FBT: Faecal blood test; FBC: 
Full blood count; ESR: Erythrocyte sedimentation rate; CRP: C-reactive protein; PBG: Porphobilinogen; IBS: Irritable bowel syndrome; CT: Computed tomography; 
MRI: Magnetic resonance imaging.
ment of  IBS subtypes, and new agents are eagerly await-
ed. In any case, it is difficult to achieve a significant thera-
peutic improvement in global IBS symptoms[64,69,71,85,86].
There is some evidence for improvements in indi-
vidual IBS symptoms with the use of  antidiarrhoeals, 
antispasmodics, bulking agents, laxatives, tricyclic antide-
pressants and behavioural therapy. Despite evidence that 
some pharmaceutical agents benefit the treatment of  IBS 
in the short term, there is no medical intervention that 
has been proven to alter the long-term natural history of  
this condition. Further, there is no agreement on a gold-
standard for the treatment of  IBS. Finally, in functional 
GI disorders, in which the trial endpoints are likely to 
be less tangible than organic conditions, the placebo re-
sponse rate may be very high (over 40%)[82]. Table 4 sum-
marises the various drug categories and their relationships 
with individual IBS symptoms.
Education and reassurance
A strong physician-patient relationship should be the 
foundation for effective treatment and realistic expecta-
tions. Responding to all patient concerns and questions 
and spending time in the clinical visits validate their 
condition. A reassurance-based approach permits the 
patient to understand and accept his or her affliction and 
to participate in a care strategy. Using this approach, a 
decrease in the number of  health care visits, a reduction 
in symptoms, and improved patient satisfaction can be 
easier obtained.
Diet
Patients with IBS commonly believe that specific dietary 
products contribute to their symptoms of  abdominal 
discomfort, bloating, or alterations of  bowel habits. The 
truth is that no specific food is likely implicated, as true 
food allergies and intolerances are rare. In many cases, 
IBS patients have an exaggerated gastric-colic reflex after 
eating certain foods.
Patients can associate with their complaints the in-
gestion of  certain foods, such as fatty foods, caffeine, 
alcoholic beverages, carbonated foods, or gas-producing 
foods. Specifically, symptoms can be related to FOD-
MAPs, such as fructans, galactans, lactose, fructose, sor-
bitol, xylitol, and mannitol[87]. Studies supporting this are 
limited and demonstrate a partial improvement in patients 
after the restriction of  these foods. Otherwise, a lactose-
restricted diet does not seem to produce a clear clinical 
benefit in IBS. Beyond this, recent evidence has shown 
that lactose intolerance was equally prevalent among IBS 
patients and the general population[64]. Finally, a recent 
study showed that patients with IBS but without celiac 
disease may reach satisfactory symptom control with a 
gluten-free diet but may suffer a symptom relapse after 
a gluten rechallenge[61]. Only a double-blind gluten chal-
lenge can discriminate between IBS and gluten-sensitivity 
patients. In any case, some care should be taken to avoid 
an unnecessarily restrictive diet with potentially serious 
nutritional consequences.
Fibre and bulking agents
Most physicians recommend the use of  dietary fibre and 
bulking agents to regularise bowel function and to reduce 
meteorism and pain in patients with IBS. The quality of  
the evidence supporting this recommendation, however, 
is poor. Some randomised placebo controlled trials have 
compared the effectiveness of  increasing the dietary 
content of  soluble fibre (psyllium and ispaghula) or in-
soluble fibre (bran) in patients with IBS and constipation. 
There is some evidence that patients taking psyllium have 
significant symptom relief, whereas bran shows no clini-
cal benefit and actually may worsen symptoms in many 
cases[64,69,71,73,85,86,88].
Antispasmodic agents
The rationale for using antispasmodic agents is to attenu-
ate the postprandial abdominal pain seen in patients with 
IBS. The mechanisms of  action of  different antispas-
modics can be divided broadly into those that directly af-
fect the intestinal smooth muscle and those with anticho-
linergic/antimuscarinic effects[64,69,71,85,86]. The evidence for 
the effectiveness of  these agents is not compelling.
One meta-analysis demonstrated an advantage of  
antispasmodics over placebo in terms of  abdominal pain 
and distention[88]. Of  all of  the drugs studied, the most 
data were available for otilonium, trimebutine, cimetro-
pium, hyoscine, and pinaverium. Trimebutine seemed 
to have no benefit over placebo in treating IBS, whereas 
the other four drugs all significantly reduced the risk of  
persistent symptoms after treatment. The anticholinergic 
side effects, including constipation, dry mouth, visual dis-
turbances, and urinary retention, can lead to the discon-
tinuation of  these medications. Finally, there is evidence 
for the efficacy of  some peppermint oil preparations 
(which may also act as antispasmodics) in IBS, but few 
data are available about the long-term results and adverse 
effects[88].
Anti-constipation agents
The presence or absence of  abdominal pain should be 
more useful than other associated features for charac-
terising IBS-C in comparison with chronic constipation. 
However, a clear clinical distinction is not always possible 
in clinical practice.
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Table 4  Indication of pharmacological agents in individual 
irritable bowel syndrome symptoms
Constipation Diarrhoea Pain
Soluble fibre Opioid agents Antispasmodics
Osmotic Laxative 5-HT3 antagonists Peppermint oil
5-HT4 agonists Probiotics Serotoninergic drugs
Secretagogues Antibiotics Antidepressants
Probiotics Mesalazine Herbal therapy
SSRI Colestyramine Acupuncture
Tricyclic antidepressants
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SSRI: Selective serotonin reuptake inhibitors.
Traditional laxatives: Consistent with recent reviews, a 
therapeutic trial of  traditional laxatives (i.e., osmotic laxa-
tives, stimulant laxatives), which are effective, safe, and 
generally inexpensive, should be considered for managing 
chronic constipation before newer agents (secretagogues, 
serotonin 5-HT4 receptor agonists) are used[70,88]. In par-
ticular, polyethylene glycol (PEG) is more effective than 
lactulose in increasing stool frequency and improving 
stool consistency; thus, it is considered the first choice of  
treatment for chronic constipation[70].
However, no placebo-controlled, randomised study 
of  laxatives in IBS has been published. Laxatives do not 
show a significant effect in reducing abdominal pain in 
IBS. A single small sequential study with PEG in adoles-
cents with IBS-C showed an improvement in stool fre-
quency[89].
Serotonin HT4 agonists: 5-HT4 receptor agonists in-
duce fast excitatory postsynaptic potentials in intrinsic 
neurons, release acetylcholine, and induce mucosal secre-
tion by activating submucosal neurons.
Tegaserod has been approved by the Food and Drug 
Administration (FDA) for the treatment of  IBS-C in 
women. Tegaserod is also the only 5-HT4 agonist that has 
been evaluated in an IBS-mixed population and showed 
an improvement of  global symptoms. However, this drug 
was removed from the market in 2007 because cardiovas-
cular events were found to be more frequent in tegaser-
od-treated patients than in placebo-treated patients[89,90].
Among the 5-HT4 agonists for chronic constipation, 
the most evidence in humans is available for prucalo-
pride[70,90]. The European Agency of  Medicinal Products 
approved this medication for chronic constipation in 
women for whom laxatives fail to provide an adequate 
relief  of  their bowel habits. Prucalopride accelerates GI 
and colonic transit in constipation, but no placebo-con-
trolled studies have been published, and no conclusive 
clinical evidence is available for IBS patients[90].
Intestinal secretagogues: By stimulating the efflux of  
ions and water into the intestinal lumen, secretagogues 
accelerate transit and facilitate defecation. Both lubipro-
stone and linaclotide increase intestinal chloride secre-
tion by activating channels on the luminal enterocyte 
surface[90]. Lubiprostone works by activating apical CIC-2 
chloride channels and does not affect colonic motor ac-
tivity in healthy subjects. It is approved by the FDA for 
the treatment of  women with IBS-C[91,92]. Linaclotide is a 
guanylyl cyclase C agonist that accelerates colonic transit 
in patients with IBS-C and chronic constipation[93]. In 
a recent randomised double-blind trial, linaclotide was 
shown to improve abdominal pain and discomfort in 
IBS-C, compared with placebo, over 12 and 26 wk[94]. In 
the same trial, diarrhoea was the most common adverse 
effect (19%), although few patients (5.7%) discontinued 
the drug as a result of  this symptom. As of  2012, lina-
clotide is approved both by the FDA and also by the Eu-
ropean Agency for the treatment of  IBS-C.
Antidiarrhoeal agents
Opioid analogues: The opioid analogues loperamide 
and diphenoxylate stimulate inhibitory presynaptic recep-
tors in the enteric nervous system, resulting in the inhibi-
tion of  peristalsis and secretion. Loperamide has been 
shown to be effective in decreasing stool frequency and 
improving stool consistency across all studies[64,69,71,85,95], 
although it provided no significant improvement in global 
IBS symptoms (in particular, abdominal pain and disten-
sion) compared with placebo.
The simultaneous μ opioid agonist and δ opioid an-
tagonist eluxadoline could reduce abdominal pain and 
diarrhoea in patients with IBS-D, compared with placebo, 
in a phase 2 study awaiting publication[96].
Serotonin HT3 antagonists: The 5-HT3 receptor an-
tagonists have been studied in IBS-D because they slow 
GI transit and decrease discomfort during the distension 
of  the colon[64,69,71,85,86]. Ondansetron is the only 5-HT3 
receptor antagonist available in Europe and is licensed 
as an antiemetic, although it is not approved for use as a 
treatment for IBS[86]. The selective 5-HT3 receptor antag-
onist alosetron was currently indicated for the treatment 
of  women with severe IBS-D who had chronic symp-
toms of  IBS[64,69,86,97].
Although it was originally approved by the FDA in 
2000, alosetron was withdrawn from the market following 
reports of  serious complications, including constipation, 
ischemic colitis, and bowel perforation, being associated 
with its use. Some evidence is available regarding other 
5-HT3 antagonists, such as cilansetron and ramosetron. 
In a recent double-blind randomised trial of  539 IBS-D 
patients, a positive response to ramosetron treatment was 
reported compared to patients receiving a placebo[98].
Bile acid binder: Some studies have indicated that a sig-
nificant number of  IBS-D patients can have mild to se-
vere bile acid malabsorption. Several studies have shown 
a dose-response relationship between the severity of  mal-
absorption and treatment with colestyramine, a bile acid 
binder[99].
Mesalazine: Mesalazine has intestinal anti-inflammatory 
properties, including cyclooxygenase and prostaglandin 
inhibition. A recent study showed that Mesalazine can 
reduce key symptoms of  postinfectious IBS and nonin-
fective IBS-D[100]. The results of  an ongoing randomised 
trial of  mesalazine in a group of  IBS-D patients will be 
soon available[101].
Antibiotics and probiotics
Treatments aimed at altering or modifying the gut mi-
crobiota, including antibiotics and probiotics, have been 
the focus of  a large number of  recent studies on IBS 
patients[5,97,102,103].
Rifaximin is a semi-synthetic derivative of  rifamycin 
with an additional benzimidazole ring that prevents its 
systemic absorption. A number of  recent clinical trials 
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have evaluated the efficacy and safety of  rifaximin in IBS 
patients (generally IBS-D). A recent systematic review 
and a meta-analysis[102,103] found rifaximin to be more ef-
ficacious than placebo for global IBS symptom improve-
ment. The most common adverse events with rifaximin 
were headache, upper respiratory infection, diarrhoea, 
and abdominal pain. Serious side effects, however, were 
rare, and their prevalences were similar between rifaxi-
min and placebo. Few data are available regarding other 
antibiotics. A subanalysis of  a double-blind, randomised, 
placebo-controlled trial demonstrated that treatment with 
neomycin improved global symptoms in individuals with 
IBS-C compared with placebo[103].
Probiotics have demonstrated benefits for some 
symptoms, notably bloating and flatulence, and involve 
a variety of  probiotic agents, including lactobacilli, bi-
fidobacteria and streptococcus. Lactobacilli alone had 
no impact on symptoms, whereas probiotic combina-
tions improved symptoms in IBS patients. Furthermore, 
there was a positive trend indicating that bifidobacteria 
improves IBS symptoms[71,85,86,96]. In a recent systematic 
review[104], probiotics appeared to be efficacious for IBS, 
but the magnitude of  their benefit and the most effective 
species have not yet been completely established. Finally, 
probiotics have no serious side effects, and there is no 
significant difference in the observed adverse events be-
tween probiotics and placebo.
Psychological therapies
Among patients with IBS, the majority have anxiety, de-
pression, or features of  somatisation. Good patient com-
pliance is necessary to achieve a successful clinical result 
after a psychotherapeutic approach or after the adminis-
tration of  antidepressants.
Psychotherapy: Among various psychological therapies, 
there is evidence for a benefit from cognitive behavioural 
therapy, dynamic psychotherapy, and hypnotherapy, but 
not from relaxation therapy[105-107]. The abnormal process-
ing and enhanced perception of  visceral stimuli in IBS 
can be normalised by psychological interventions. Psy-
chotherapy is particularly successful in patients who re-
ported a history of  sexual abuse. Psychological therapies 
are not documented to have any serious adverse effects.
Tricyclic antidepressants: Tricyclic antidepressants 
(TCAs) are drugs with anticholinergic and non-selective se-
rotonin reuptake inhibitor effects. Antidepressants could 
theoretically provide a benefit in IBS by both central and 
peripheral mechanisms[64,71,85,86,97]. Five tricyclic agents 
have been studied formally (amitriptyline, trimipramine, 
desipramine, clomipramine, and doxepin), and the effects 
of  these agents are primarily related to pain. It has been 
suggested that patients with IBS-D obtain the greatest 
benefit from this approach[67]. The side effects of  consti-
pation, dry mouth, drowsiness, and fatigue occur in over 
one-third of  IBS patients treated with TCAs, which often 
precludes good patient compliance.
Selective serotonin reuptake inhibitors, antidepres-
sants: Physicians often prefer selective serotonin reuptake 
inhibitors (SSRIs) over TCAs because of  their lower side-
effect profiles. SSRIs, such as paroxetine and fluoxetine, 
can accelerate whole gut transit and are considered poten-
tially effective in the treatment of  IBS-C. A large trial[71] 
showed that a standard dose of  an SSRI antidepressant 
led to a significant improvement in the health-related 
quality of  life in patients with IBS, but no significant ef-
fects were observed in bowel habits or pain. However, in 
a double-blind randomised trial, fluoxetine was effective in 
decreasing global symptoms in the short-term therapy of  
a group of  IBS-C patients[104].
Alternative approaches
Chinese herbal preparations have also been the subject 
of  several trials[108]. By combining the effects of  Iberis 
amara on smooth muscle tone with the spasmolytic ef-
fects of  other plants, Iberogast, a popular combination 
of  nine herbal plants, exerts a dual action on smooth 
muscle, stimulating or spasmolytic, depending on func-
tional baseline conditions. These plant preparations have 
been shown to improve overall IBS scores and abdomi-
nal pain, but it is unclear which component is the active 
ingredient. A longer study of  16 wk with Chinese herbal 
preparations reported significant symptom improve-
ment[109]. No conclusive data are available regarding any 
toxicity, especially regarding liver failure, of  any Chinese 
herbal mixture.
Another popular alternative treatment concerns the 
use of  acupuncture in IBS. A Cochrane review of  six 
trials with a median sample size of  54 found insufficient 
evidence to determine whether acupuncture is an effec-
tive treatment for IBS[110]. In a recent open randomised 
trial, acupuncture for IBS provided an additional benefit 
over the usual care alone in a primary care experience[111].
Further studies are needed before any final recom-
mendations on acupuncture or herbal therapy can be 
made.
CONCLUSION
Even though there is some evidence that changes in the 
digestive motility and secretion, visceral hypersensitivity, 
abnormalities of  enteroendocrine and immune systems, 
genetic factors, infections, alterations of  the intestinal 
microbiota and inflammation could play a role in IBS, its 
pathogenesis remains only partially understood. Thus, 
in clinical practice, its management is quite difficult. Be-
cause no biological markers are available, diagnoses can 
be made only on the basis of  the symptoms described by 
the Rome Ⅲ criteria, for example. Unfortunately, many 
physicians do not use these criteria in their clinical prac-
tice and instead, driven by their own concerns or the con-
cern of  their patients, often prescribe many unnecessary 
diagnostic tests.
Furthermore, IBS therapy is far from satisfactory. The 
cornerstone for any effective treatment strategy should 
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be a solid patient-physician relationship; indeed, this re-
lationship should be individualised for each patient. To 
achieve this goal, the use of  combination drug therapies 
may be suggested. The data reviewed here indicate that 
there is limited evidence to support the individual efficacy 
of  any of  the agents currently available.
In conclusion, the pathogenesis, diagnosis and treat-
ment of  IBS remain subjects of  much ongoing research. 
Further well-structured studies are needed to improve 
our knowledge about IBS and its management.
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